A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy
Latest Information Update: 19 Mar 2024
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms POLAR
- 13 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 13 Mar 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 06 Jun 2023 Results from Cohorts B & C, presented at the 59th Annual Meeting of the American Society of Clinical Oncology